We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Pneumococcal Immune Status Accurately Determined in Saliva Samples

By LabMedica International staff writers
Posted on 27 Dec 2016
Print article
Image: A fluorescent micrograph of Streptococcus pneumoniae in spinal fluid (Photo courtesy of the CDC).
Image: A fluorescent micrograph of Streptococcus pneumoniae in spinal fluid (Photo courtesy of the CDC).
Measurement of levels of antibodies against 12 Streptococcus pneumoniae antigens in saliva was shown to provide as accurate an indication of immune status against this organism as was determination of antibody levels in blood serum.

The objective of a study carried out at the University of Birmingham United Kingdom) was to assess if levels of anti-pneumococcal (Pn) antibodies in saliva reflected concentrations in serum and to determine whether saliva could accurately identify protective concentrations in serum.

Toward this end the investigators employed a multiplex assay, the BioRad Laboratories (Hercules, CA, USA) Luminex-200, Bioplex System, that simultaneously measured antibody concentrations against 12 Pn antigens, to determine IgG, IgA, and IgM antibody levels in paired saliva and serum samples against 12 Pn polysaccharide antigens in 72 healthy adults.

Results revealed that antibody levels in saliva correlated positively with serum across immunoglobulin classes, most strongly for IgA. Individuals who had protective antibody levels in serum demonstrated significantly higher IgG and IgA salivary antibody concentrations and secretion rates. Salivary IgG and IgA Pn antibodies were able to distinguish between those with/without protective levels in serum for the majority of serotypes. Salivary IgM antibodies were not able to differentiate protective status.

First author Dr. Jennifer Heaney, a researcher in immunity and infection at the University of Birmingham, said, "Protection against bacterial infection is usually inferred by measuring antibody levels in blood serum. But taking blood samples involves a number of logistical considerations and may not always be feasible, especially in developing countries or where children are involved. Saliva sampling is non-invasive, requires no specialist training or equipment, and may be more cost-effective. The suggestion that antibody levels in saliva may be indicative of those in serum therefore has important implications for markers of immunity and vaccination in many parts of the world. This research highlights the need for larger studies further to investigate the potential of saliva testing as a tool to assess immunity."

The study was published in the December 12, 2016, online edition of the journal Biomarkers.

Related Links:
University of Birmingham
BioRad Laboratories

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test
New
Basophil Activation Test
Flow CAST Kit
New
PROM Test
AMNIOQUICK DUO

Print article

Channels

Molecular Diagnostics

view channel
Image: A coronal MRI section shows a high-intensity focused ultrasound lesion in the left thalamus of the brain (Photo courtesy of UT Southwestern Medical Center)

Newly Identified Stroke Biomarkers Pave Way for Blood Tests to Quickly Diagnose Brain Injuries

Each year, nearly 800,000 individuals in the U.S. experience a stroke, which occurs when blood flow to specific areas of the brain is insufficient, causing brain cells to die due to a lack of oxygen.... Read more

Immunology

view channel
Image: The discovery of biomarkers could improve endometrial cancer treatment (Photo courtesy of Mount Sinai)

Simple Blood Test Could Help Choose Better Treatments for Patients with Recurrent Endometrial Cancer

Endometrial cancer, which develops in the lining of the uterus, is the most prevalent gynecologic cancer in the United States, affecting over 66,000 women annually. Projections indicate that in 2025, around... Read more

Pathology

view channel
Image: As tumor cells flow through these microfluidic chambers, they are subjected to increasing shear stress and sorted based on their adhesion strength (Photo courtesy of UC San Diego)

Microfluidic Device Assesses Stickiness of Tumor Cells to Predict Cancer Spread

Ductal carcinoma in situ (DCIS), a type of early-stage breast cancer, is often referred to as stage zero breast cancer. In many cases, it remains harmless and does not spread beyond the milk ducts where... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.